Rubix LS Rubix Life Sciences
Menu Button

Rubix LS

Delivering precision insight to create precision therapeutics with inclusive patient data

Connecting and powering the world's healthcare data through diversity patient analytics

Precision health research data points

13
Countries Supported
1,760
Disease & Cancers Supported

Data Research & Analytics

Clinical Research

Consulting

Therapeutic Research

Federal Programs

Enable Patient Inclusivity. For
Better Health Outcomes


Data Research & Analytics

Clinical Research

Consulting

Therapeutic Research

Federal Programs

Blending the power of Data, AI, Technology,
Medicine and Genomics to Craft Better Health
Advancements
Working through roadblocks to bring
inclusivity into early & late stage trials
with precision outcomes for all
Designing patient centricity with specific
scientific expertise
Diving deep into enormous data sets, we're
centrally focused on creating the therapies
broad communities are needing
Collective knowledge of 60+ years
in federal program work. Combating future
health threats is our goal

Precision Delivery

Using data and digital health to accelerate research to overcome disease and cancer health disparities

01

Characterize big data sets along with patient trends

02

Using precision intelligence, design and optimize clinical research to underserved communities using patient centric methodologies

03

Scale data for RWE and purpose data for therapeutic and healthcare innovation

Specialties

Uncovering the holistic picture to determine best paths of cancer and disease causes while developing targeted precision medicine strategies

Infectious Disease

Infectious Disease

Rare & Ultra Rare

Rare & Ultra Rare

Environmental

Environmental

Oncology

Oncology

Vision for Greater Clinical Trial Patient Diversity

Rubix CEO Outlines Vision for Greater Clinical Trial Patient Diversity

"We want to make sure that we put data into action to diversify the clinical trial patient population,” Reginald Swift, founder and CEO, Rubix LS told attendees of a panel at ATA2022 in Boston in early May 2022.   “As we look to expand telehealth’s role in clinical trials, we...

Time to Educate Minority Populations

It’s Time to Educate Minority Populations About the Benefits of Clinical Trials

By Reginald Swift, founder/CEO, Rubix LS Fresh off attending the ASCO 2022 conference, I was heartened to hear how much attention was focused on promoting minority participation in clinical trials. We all know it is the right thing to do morally, but it is also clear that diverse populations generate...

Rubix LS Applauds FDA Draft Guidance Calling for Enhanced Clinical Trial Diversity

“The moral, scientific, and business cases for promoting diversity in clinical trials have never been clearer,” says Reginald Swift, Ph. D, founder/CEO at Rubix Life Sciences. “It’s time to truly promote clinical trial diversity by harnessing data and working with experts who understand cultural nuances, especially for traditionally underserved patient...